BioInvent International AB: Interim report January-June 2024 Page 1

LUND, SWEDEN / ACCESSWIRE / August 29, 2024 / BioInvent International (STO:BINV)

“The presentation of promising results from our two lead drug candidates at the ASCO Annual Meeting demonstrated their potential as leading immunomodulatory agents and ushered in a data-rich period for BioInvent. We expect to report results from all six of our clinical programs in the future.” – Martin Welschof, CEO of BioInvent.

EVENTS IN THE SECOND QUARTER
• (R) Additional Phase 1/2a data for BI-1206 with rituximab in NHL presented at EHA 2024, with promising early efficacy data from the SC arm
• (R) Clinical efficacy and safety of the anti-TNFR2 agent BI-1808 presented at ASCO 2024, demonstrating the activity of BI-1808 as a single agent, a potential novel class of immunomodulatory agents
• Patent for BI-1808 approved in China
• (R) Phase 1 data for BI-1206 in combination with KEYTRUDA (pembrolizumab) in solid tumors presented at ASCO 2024; demonstrate responses in melanoma patients who previously failed anti-PD1 therapy
• Poster with model-driven early clinical development of anti-TNFR2 agent BI-1808 presented at PAGE 2024, to support dose selection and optimization of clinical development
• New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody, in combination with KEYTRUDA (pembrolizumab)

EVENTS AFTER THE END OF THE PERIOD
• The subcutaneous (SC) formulation of BI-1206 has been selected for the upcoming Phase 2a study in combination with rituximab and acalabrutinib for the treatment of NHL
• Notice of approval received from USPTO for BI-1910 patent application
• New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1607, the company’s second anti-FcγRIIB antibody, in combination with KEYTRUDA (pembrolizumab) and ipilimumab
• Two programs to be presented at ESMO 2024: the company’s second anti-TNFR2 antibody BI-1910 and the oncolytic virus BT-001, equipped with BioInvent’s anti-CTLA-4 antibody

(R)= Regulatory event

FINANCIAL INFORMATION
Second quarter 2024

• Net sales, SEK 4.6 (13.1) million

• Profit/loss after tax, SEK -137.3 (88.3) million

• Profit/loss after tax per share before and after dilution, SEK -2.09 (1.34)

• Cash flow from operating activities, SEK -119.2 (-84.1) million

• Cash, current and long-term investments at the end of the period, SEK 1,090.3 (1,461.7) million

January – June 2024